{"entity":{"id":"relapsed-refractory-hodgkin-lymphoma","kind":"cancer","name":"Relapsed and refractory classical Hodgkin lymphoma","aka":["Relapsed Hodgkin lymphoma","Refractory Hodgkin lymphoma","R/R cHL","Hodgkin lymphoma after first-line failure"],"tldr":"Relapsed or refractory classical Hodgkin lymphoma is Hodgkin lymphoma that comes back or does not respond after first-line chemotherapy. The standard path is salvage chemotherapy, often with brentuximab vedotin or a PD-1 antibody, then high-dose chemotherapy with an autologous stem cell transplant; for those who relapse again, nivolumab and pembrolizumab give lasting control in many.","summary":"Classical Hodgkin lymphoma that relapses after or is refractory to first-line therapy has been treated since the 1990s with salvage chemotherapy (ICE, DHAP, GVD, bendamustine-based regimens) followed by high-dose chemotherapy with autologous stem cell transplantation, which cures about half of patients; achieving a PET-negative remission before transplant is the strongest predictor of cure. Two classes of drug then transformed the field. Brentuximab vedotin, an antibody-drug conjugate against CD30, produced responses in three quarters of patients relapsing after transplant in its pivotal trial and was approved in 2011, and the AETHERA trial (Lancet 2015) showed that giving it as consolidation after transplant to high-risk patients lengthened progression-free survival from 24.1 to 42.9 months. PD-1 antibodies exploit the near-universal 9p24.1 amplification of PD-L1 in Reed-Sternberg cells: nivolumab (CheckMate 205) and pembrolizumab (KEYNOTE-087) produced responses in about two thirds of heavily pretreated patients and were approved in 2016 and 2017, and KEYNOTE-204 (Lancet Oncology 2021) showed pembrolizumab beat brentuximab vedotin in relapsed disease with progression-free survival of 13.2 against 8.3 months.\n\nThese agents have moved earlier. Salvage regimens now combine brentuximab vedotin or a PD-1 antibody with chemotherapy or with each other (brentuximab-nivolumab, pembrolizumab-GVD) to reach PET-negative remission in more patients before transplant, and trials ask whether some patients with a complete response to immunotherapy-based salvage can skip transplantation altogether. After failure of transplant, brentuximab vedotin and a PD-1 antibody, allogeneic transplantation, which can cure a minority with acceptable risk after PD-1 blockade with careful management, and clinical trials of CD30-directed CAR T cells (CHARIOT), bispecific antibodies and novel combinations are the options; older agents such as bendamustine, gemcitabine and everolimus retain a role. Because first-line nivolumab-AVD and brentuximab-AVD are now standard, the definition of relapse after these regimens and the best salvage for patients already exposed to both classes is the open question, and cardiac, pulmonary and second-cancer late effects of cumulative therapy need lifelong attention.","asOf":"2026-09-18","wikipedia":"https://en.wikipedia.org/wiki/Hodgkin_lymphoma","links":[{"label":"AETHERA (Lancet 2015)","url":"https://doi.org/10.1016/S0140-6736(15)60165-9"},{"label":"KEYNOTE-204 (Lancet Oncology 2021)","url":"https://doi.org/10.1016/S1470-2045(21)00005-X"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Hodgkin_lymphoma"},{"label":"Lymphoma Action: helpline services","url":"https://lymphoma-action.org.uk/information-and-support/support-you/helpline-services"},{"label":"Lymphoma Action: questions to ask your medical team about lymphoma","url":"https://lymphoma-action.org.uk/information-and-support/tests-scans-and-lymphoma-staging/questions-ask-your-medical-team-about-lymphoma"},{"label":"Lymphoma Action: follow-up after lymphoma treatment","url":"https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/follow-after-lymphoma-treatment"},{"label":"Lymphoma Action: infections, risk and prevention","url":"https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/infections-risk-and-prevention"},{"label":"Lymphoma Action: neutropenia (low neutrophils)","url":"https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/neutropenia-low-neutrophils"},{"label":"Lymphoma Action: cancer-related fatigue","url":"https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/cancer-related-fatigue"},{"label":"Lymphoma Action: lymphoma, work and you","url":"https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/day-day-living/lymphoma-work-and-you"},{"label":"Maggie's: support and information","url":"https://www.maggies.org/support-and-information/"},{"label":"Lymphoma Action: autologous (your own) stem cell transplant","url":"https://lymphoma-action.org.uk/information-and-support/lymphoma-treatment/stem-cell-transplants/self-autologous-stem-cell"},{"label":"Lymphoma Action: when lymphoma comes back, or does not respond","url":"https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/lymphoma-comes-back-relapses-or-doesnt-respond"},{"label":"Lymphoma Action: CAR-T cell therapy","url":"https://lymphoma-action.org.uk/information-and-support/lymphoma-treatment/car-t-cell-therapy"},{"label":"Lymphoma Action: late effects of lymphoma treatment","url":"https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/late-effects-lymphoma-treatment"}],"tags":["subtype-page","haematologic"],"related":["advanced-stage-classical-hodgkin-lymphoma","early-stage-classical-hodgkin-lymphoma","hodgkin-lymphoma","dlbcl"],"cancers":[],"sections":[],"technologies":["autologous-stem-cell-transplant","allogeneic-hsct","adc","checkpoint-inhibitor","fdg-pet","imrt-igrt","ctdna-lymphoma-monitoring","car-t","palliative-care","psycho-oncology","peer-support-groups","survivorship-care-plan","fertility-preservation","financial-navigation","cbt-fatigue-distress","exercise-during-chemotherapy","multidisciplinary-tumour-board","oncology-nutrition","prehabilitation"],"targets":["cd30","pd1","pdl1"],"drugs":["brentuximab-vedotin","nivolumab","pembrolizumab","penpulimab","gemcitabine","everolimus"],"companies":[],"institutions":[],"pathways":[],"terms":["deauville-score","reed-sternberg-cell","late-effects","lymphoma-tx-radiotherapy","lymphoma-tx-hodgkin-late-effects","lymphoma-tx-fertility-preservation","lymphoma-tx-transplant-role","lymphoma-tx-uk-versus-us","lymphoma-tx-uk-access","lymphoma-tx-regimen-alphabet","cancer-related-fatigue","febrile-neutropenia","neutropenia","financial-toxicity","central-venous-access","hypogammaglobulinaemia","performance-status","quality-of-life","lymphoma-decision-local-or-car-t-centre","lymphoma-decision-trial","lymphoma-living-hodgkin-survivorship-screening","lymphoma-living-infection-years-after","lymphoma-living-fatigue"],"trials":["aethera","keynote-204","checkmate-205","nct04268706"],"people":[],"bottlenecks":[],"keyPapers":["paper-keynote-204-pembrolizumab-vs-brentuximab-rr-hodgkin-lancet-oncol-2021","paper-aethera-brentuximab-consolidation-after-asct-hodgkin-lancet-2015","paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018"],"journals":[],"dependsOn":[],"notes":["Relapsed Hodgkin lymphoma, the transplant route and what living near a centre asks of a household: This is orientation from public patient pages, guidelines and the trials themselves, not advice for your case: your own team's instructions and the 24-hour number they gave you come first, and no figure here is a prediction about you. The decision records, the question sets, the first 60 days checklist and the red cards on this page were written from the NHS, Lymphoma Action, Macmillan and Cancer Research UK patient pages, from NICE NG52, NG47, CG151 and NG234, from the NHS Breast Screening Programme protocols and the Green Book, and from the trial reports named beside each figure, all read on 1 October 2026."],"group":"haematologic","burden":"A tenth to a quarter of classical Hodgkin lymphoma relapses or fails to respond to first-line treatment; most of these patients are still cured with salvage chemotherapy and transplantation, and immunotherapy has changed the outlook for the rest.","subtypes":["Primary refractory classical Hodgkin lymphoma (no complete response to first line)","Early relapse within twelve months of first-line therapy","Late relapse after twelve months (favourable, may be retreated with less)","Relapsed classical Hodgkin lymphoma after autologous transplantation (brentuximab vedotin, PD-1 antibodies, allogeneic transplant)","Relapse after first-line brentuximab-AVD or nivolumab-AVD","Multiply relapsed classical Hodgkin lymphoma (CAR T and bispecific trials)"],"biomarkers":["PET-negative remission before transplant (Deauville 1 to 3; strongest predictor of cure)","Time to relapse (under or over twelve months) and primary refractory status","Extranodal disease, B symptoms and prior lines (AETHERA high-risk criteria)","CD30 expression (brentuximab target)","9p24.1 amplification and PD-L1 expression (PD-1 responsiveness)","Circulating tumour DNA (research)"],"standardOfCare":[{"setting":"Salvage before transplant","approach":"Platinum-based chemotherapy (ICE, DHAP, GVD) increasingly combined with brentuximab vedotin or pembrolizumab, or brentuximab vedotin with nivolumab, to reach PET-negative remission.","refs":["brentuximab-vedotin","nivolumab","pembrolizumab","gemcitabine","fdg-pet","deauville-score"],"guideline":{"version":"NCCN Guidelines: Hodgkin Lymphoma","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1439"}},{"setting":"Consolidation","approach":"High-dose chemotherapy with autologous stem cell transplantation for chemosensitive relapse; brentuximab vedotin maintenance for a year in high-risk patients (AETHERA).","refs":["autologous-stem-cell-transplant","brentuximab-vedotin","aethera"],"guideline":{"version":"NCCN Guidelines: Hodgkin Lymphoma","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1439"}},{"setting":"Relapse after transplant","approach":"Pembrolizumab (KEYNOTE-204) or nivolumab (CheckMate 205); brentuximab vedotin if not previously given; PD-1 antibodies in China include penpulimab and others.","refs":["pembrolizumab","keynote-204","nivolumab","checkmate-205","brentuximab-vedotin","penpulimab","checkpoint-inhibitor"],"guideline":{"version":"NCCN Guidelines: Hodgkin Lymphoma","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1439"}},{"setting":"Failure of PD-1 antibodies and brentuximab","approach":"Allogeneic transplantation for fit patients; bendamustine, gemcitabine or everolimus; CD30 CAR T cells and bispecific antibodies in trials.","refs":["allogeneic-hsct","gemcitabine","everolimus","nct04268706","idea-cd30-car-t-hodgkin"],"guideline":{"version":"NCCN Guidelines: Hodgkin Lymphoma","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1439"}},{"setting":"Transplant-ineligible patients","approach":"PD-1 antibody with or without brentuximab vedotin as ongoing therapy; palliative radiotherapy for symptomatic sites.","refs":["nivolumab","brentuximab-vedotin","imrt-igrt"],"guideline":{"version":"NCCN Guidelines: Hodgkin Lymphoma","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1439"}},{"setting":"First relapse of classical Hodgkin lymphoma: salvage to a negative PET, then autologous transplant","approach":"The aim of salvage treatment is not a response but a negative PET, because the proportion of patients cured by the transplant that follows depends more on the depth of the remission before it than on which salvage regimen produced it.\n\nSalvage regimens in use: brentuximab vedotin with bendamustine; brentuximab vedotin with nivolumab, which produces high complete response rates without chemotherapy; ICE or IGEV or DHAP or ESHAP. There is no randomised trial ranking them, and the choice is made on toxicity, on stem cell mobilisation and on what the patient has already had. Two to three cycles, then a PET; if it is negative, proceed to BEAM conditioning and autologous transplant; if it is positive, change salvage rather than proceeding.\n\nConsolidation after transplant with brentuximab vedotin is standard for patients at high risk of relapse, on the strength of AETHERA, which randomised 329 such patients to brentuximab vedotin or placebo and gave median progression-free survival of 42.9 against 24.1 months (hazard ratio 0.57). High risk means primary refractory disease, relapse within twelve months, or extranodal disease at relapse. Patients who received brentuximab vedotin in first-line treatment are a group in whom this is less clear.","refs":["aethera","brentuximab-vedotin","nivolumab","bendamustine","ifosfamide","carboplatin","etoposide","cisplatin","cytarabine","carmustine","melphalan","autologous-stem-cell-transplant","fdg-pet","deauville","lymphoma-tx-transplant-role","paper-aethera-brentuximab-consolidation-after-asct-hodgkin-lancet-2015"],"guideline":{"nccn":"Category 1 (brentuximab vedotin consolidation, high-risk)","version":"NCCN Hodgkin Lymphoma; ESMO; AETHERA","url":"https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq"}},{"setting":"Relapse after autologous transplant, or where transplant is not possible: PD-1 blockade","approach":"Classical Hodgkin lymphoma has amplification of chromosome 9p24.1, which drives expression of PD-L1 and PD-L2, and it is the disease in which PD-1 blockade works best of all.\n\nNivolumab. CheckMate 205 treated 243 patients after autologous transplant failure and reported an objective response of 69 per cent, with responses lasting in many. It is also active after both autologous transplant and brentuximab vedotin have failed.\n\nPembrolizumab. KEYNOTE-204 randomised 304 patients with relapsed or refractory classical Hodgkin lymphoma to pembrolizumab or brentuximab vedotin and gave median progression-free survival of 13.2 against 8.3 months (hazard ratio 0.65), which established PD-1 blockade as preferred over brentuximab vedotin at this point for patients who have had one or the other.\n\nCombinations of brentuximab vedotin with nivolumab are used as a bridge to transplant and in later lines. Where a response is achieved in a fit younger patient who has already had an autologous transplant, an allogeneic transplant with reduced-intensity conditioning is considered, although PD-1 blockade before allogeneic transplant increases the risk of severe graft-versus-host disease and the timing has to be planned with the transplant team.","refs":["checkmate-205","keynote-204","nivolumab","pembrolizumab","brentuximab-vedotin","allogeneic-hsct","paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018","paper-keynote-204-pembrolizumab-vs-brentuximab-rr-hodgkin-lancet-oncol-2021"],"guideline":{"nccn":"Category 1","version":"NCCN Hodgkin Lymphoma; ESMO; KEYNOTE-204, CheckMate 205","url":"https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq"}},{"setting":"After brentuximab vedotin and PD-1 blockade have both failed","approach":"This is a small group and there is no standard. Options, roughly in the order they are usually considered: re-treatment with a PD-1 antibody after a chemotherapy-induced response, because chemotherapy can restore sensitivity; an allogeneic transplant with reduced-intensity conditioning in a fit younger patient, which is the only treatment with curative potential; anti-CD30 CAR-T, which has produced responses in phase 1 and 2 studies and is not approved; gemcitabine-based or single-agent chemotherapy for control; involved-site radiotherapy for a symptomatic site, which is highly effective in a radiosensitive disease; and a clinical trial, which at this point is often the best available treatment.\n\nThe conversation about aim belongs here explicitly. Palliative radiotherapy and low-intensity chemotherapy can give good quality of life for a long time in Hodgkin lymphoma, and early involvement of a palliative care team alongside oncology is recommended rather than deferred.","refs":["brentuximab-vedotin","nivolumab","pembrolizumab","gemcitabine","bendamustine","allogeneic-hsct","car-t","palliative-radiotherapy","palliative-care","paper-cd30-hodgkin-lymphoma-j-clin-oncol-2020"],"guideline":{"version":"NCCN Hodgkin Lymphoma; no standard beyond this point","url":"https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq"}}],"stateOfArt":["Immunotherapy-based salvage gets more patients to a PET-negative transplant and may let some skip it.","PD-1 antibodies give durable control to many patients who relapse after transplant.","CD30 CAR T cells and bispecific antibodies are the next layer for multiply relapsed disease."],"history":[{"year":1993,"title":"Randomised trial confirms autologous transplantation improves outcomes in relapsed Hodgkin lymphoma","refs":["autologous-stem-cell-transplant"]},{"year":2011,"title":"Brentuximab vedotin approved for relapsed Hodgkin lymphoma after transplant","refs":["brentuximab-vedotin","cd30"]},{"year":2015,"title":"AETHERA: brentuximab vedotin consolidation after transplant lengthens progression-free survival","refs":["aethera","brentuximab-vedotin"]},{"year":2016,"title":"Nivolumab approved after CheckMate 205","refs":["nivolumab","checkmate-205"]},{"year":2017,"title":"Pembrolizumab approved after KEYNOTE-087","refs":["pembrolizumab"]},{"year":2021,"title":"KEYNOTE-204: pembrolizumab beats brentuximab vedotin in relapsed disease","refs":["keynote-204","pembrolizumab","brentuximab-vedotin"]}],"pipeline":["nct04268706","idea-cd30-car-t-hodgkin","brentuximab-vedotin","pembrolizumab","nivolumab","ctdna-lymphoma-monitoring"],"openProblems":["Which patients in complete remission after immunotherapy salvage can safely skip transplantation is unproven.","Salvage for patients already exposed to brentuximab and PD-1 antibodies in first line is undefined.","Allogeneic transplant after PD-1 blockade carries a risk of severe graft-versus-host disease.","Cumulative cardiac and lung toxicity limits options in multiply treated patients."],"parent":"hodgkin-lymphoma"},"route":"/cancers/relapsed-refractory-hodgkin-lymphoma/","neighbours":{"cancer":[{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"early-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Early-stage classical Hodgkin lymphoma (stage I to II)","route":"/cancers/early-stage-classical-hodgkin-lymphoma/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"technology":[{"id":"allogeneic-hsct","kind":"technology","name":"Allogeneic stem cell transplantation","route":"/technologies/allogeneic-hsct/"},{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"autologous-stem-cell-transplant","kind":"technology","name":"Autologous stem cell transplant (high-dose therapy)","route":"/technologies/autologous-stem-cell-transplant/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"cbt-fatigue-distress","kind":"technology","name":"Cognitive behavioural therapy for fatigue and distress","route":"/technologies/cbt-fatigue-distress/"},{"id":"ctdna-lymphoma-monitoring","kind":"technology","name":"ctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ)","route":"/technologies/ctdna-lymphoma-monitoring/"},{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/"},{"id":"exercise-during-chemotherapy","kind":"technology","name":"Exercise during chemotherapy and radiotherapy","route":"/technologies/exercise-during-chemotherapy/"},{"id":"fdg-pet","kind":"technology","name":"FDG PET","route":"/technologies/fdg-pet/"},{"id":"financial-navigation","kind":"technology","name":"Financial toxicity and financial navigation","route":"/technologies/financial-navigation/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"multidisciplinary-tumour-board","kind":"technology","name":"Multidisciplinary tumour boards","route":"/technologies/multidisciplinary-tumour-board/"},{"id":"oncology-nutrition","kind":"technology","name":"Nutrition support and cachexia management","route":"/technologies/oncology-nutrition/"},{"id":"fertility-preservation","kind":"technology","name":"Oncofertility and fertility preservation","route":"/technologies/fertility-preservation/"},{"id":"palliative-radiotherapy","kind":"technology","name":"Palliative radiotherapy","route":"/technologies/palliative-radiotherapy/"},{"id":"peer-support-groups","kind":"technology","name":"Peer support and support groups","route":"/technologies/peer-support-groups/"},{"id":"prehabilitation","kind":"technology","name":"Prehabilitation before cancer surgery","route":"/technologies/prehabilitation/"},{"id":"psycho-oncology","kind":"technology","name":"Psycho-oncology and distress screening","route":"/technologies/psycho-oncology/"},{"id":"survivorship-care-plan","kind":"technology","name":"Survivorship care and late-effects surveillance","route":"/technologies/survivorship-care-plan/"}],"target":[{"id":"cd30","kind":"target","name":"CD30","route":"/targets/cd30/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"drug":[{"id":"bendamustine","kind":"drug","name":"Bendamustine","route":"/drugs/bendamustine/"},{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"carmustine","kind":"drug","name":"Carmustine","route":"/drugs/carmustine/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"cytarabine","kind":"drug","name":"Cytarabine","route":"/drugs/cytarabine/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"},{"id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"ifosfamide","kind":"drug","name":"Ifosfamide","route":"/drugs/ifosfamide/"},{"id":"melphalan","kind":"drug","name":"Melphalan (including hepatic delivery system)","route":"/drugs/melphalan/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"penpulimab","kind":"drug","name":"Penpulimab","route":"/drugs/penpulimab/"}],"term":[{"id":"lymphoma-decision-trial","kind":"term","name":"A clinical trial or standard treatment in lymphoma","route":"/terms/lymphoma-decision-trial/"},{"id":"lymphoma-living-hodgkin-survivorship-screening","kind":"term","name":"After Hodgkin lymphoma: the late effects, and the screening that follows them","route":"/terms/lymphoma-living-hodgkin-survivorship-screening/"},{"id":"lymphoma-tx-uk-versus-us","kind":"term","name":"British and American lymphoma practice: where they differ, and why","route":"/terms/lymphoma-tx-uk-versus-us/"},{"id":"cancer-related-fatigue","kind":"term","name":"Cancer-related fatigue (tiredness)","route":"/terms/cancer-related-fatigue/"},{"id":"cardiotoxicity","kind":"term","name":"Cardiotoxicity (LVEF decline, cardiomyopathy)","route":"/terms/cardiotoxicity/"},{"id":"central-venous-access","kind":"term","name":"Central venous access (port, PICC line)","route":"/terms/central-venous-access/"},{"id":"deauville-score","kind":"term","name":"Deauville five-point scale","route":"/terms/deauville-score/"},{"id":"deauville","kind":"term","name":"Deauville score and PET-adapted therapy","route":"/terms/deauville/"},{"id":"lymphoma-living-fatigue","kind":"term","name":"Fatigue after lymphoma treatment, and why it is a symptom to report","route":"/terms/lymphoma-living-fatigue/"},{"id":"febrile-neutropenia","kind":"term","name":"Febrile neutropenia","route":"/terms/febrile-neutropenia/"},{"id":"lymphoma-tx-fertility-preservation","kind":"term","name":"Fertility before lymphoma treatment: what to ask for, and when","route":"/terms/lymphoma-tx-fertility-preservation/"},{"id":"financial-toxicity","kind":"term","name":"Financial toxicity","route":"/terms/financial-toxicity/"},{"id":"hypogammaglobulinaemia","kind":"term","name":"Hypogammaglobulinaemia and infection risk after B-cell therapies","route":"/terms/hypogammaglobulinaemia/"},{"id":"late-effects","kind":"term","name":"Late effects and survivorship toxicity","route":"/terms/late-effects/"},{"id":"lymphoma-tx-hodgkin-late-effects","kind":"term","name":"Late effects of Hodgkin lymphoma treatment, and the follow-up that answers them","route":"/terms/lymphoma-tx-hodgkin-late-effects/"},{"id":"lymphoma-living-infection-years-after","kind":"term","name":"Low antibodies and infection risk for years after anti-CD20 and bispecific antibodies","route":"/terms/lymphoma-living-infection-years-after/"},{"id":"neutropenia","kind":"term","name":"Neutropenia","route":"/terms/neutropenia/"},{"id":"performance-status","kind":"term","name":"Performance status (ECOG, Karnofsky)","route":"/terms/performance-status/"},{"id":"quality-of-life","kind":"term","name":"Quality of life","route":"/terms/quality-of-life/"},{"id":"lymphoma-tx-radiotherapy","kind":"term","name":"Radiotherapy in lymphoma: involved-site fields, 24 Gy, 4 Gy and total skin electron therapy","route":"/terms/lymphoma-tx-radiotherapy/"},{"id":"reed-sternberg-cell","kind":"term","name":"Reed-Sternberg cell","route":"/terms/reed-sternberg-cell/"},{"id":"secondary-malignancy","kind":"term","name":"Secondary malignancy (therapy-related cancer)","route":"/terms/secondary-malignancy/"},{"id":"lymphoma-tx-transplant-role","kind":"term","name":"Stem cell transplant in lymphoma: what it is still for","route":"/terms/lymphoma-tx-transplant-role/"},{"id":"lymphoma-tx-regimen-alphabet","kind":"term","name":"The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest","route":"/terms/lymphoma-tx-regimen-alphabet/"},{"id":"lymphoma-decision-local-or-car-t-centre","kind":"term","name":"Treatment at the local hospital or at a cell-therapy centre far from home","route":"/terms/lymphoma-decision-local-or-car-t-centre/"},{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","route":"/terms/lymphoma-tx-uk-access/"}],"trial":[{"id":"aethera","kind":"trial","name":"AETHERA","route":"/trials/aethera/"},{"id":"checkmate-205","kind":"trial","name":"CheckMate 205","route":"/trials/checkmate-205/"},{"id":"keynote-204","kind":"trial","name":"KEYNOTE-204","route":"/trials/keynote-204/"},{"id":"nct04268706","kind":"trial","name":"Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)","route":"/trials/nct04268706/"},{"id":"nct00742027","kind":"trial","name":"Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma","route":"/trials/nct00742027/"},{"id":"nct01037478","kind":"trial","name":"Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma","route":"/trials/nct01037478/"}],"paper":[{"id":"paper-aethera-brentuximab-consolidation-after-asct-hodgkin-lancet-2015","kind":"paper","name":"AETHERA: brentuximab vedotin consolidation after autologous stem cell transplantation in Hodgkin lymphoma at risk of relapse","route":"/key-papers/paper-aethera-brentuximab-consolidation-after-asct-hodgkin-lancet-2015/"},{"id":"paper-cd30-hodgkin-lymphoma-j-clin-oncol-2020","kind":"paper","name":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","route":"/key-papers/paper-cd30-hodgkin-lymphoma-j-clin-oncol-2020/"},{"id":"paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018","kind":"paper","name":"CheckMate 205: nivolumab for relapsed or refractory classical Hodgkin lymphoma after autologous transplant failure, extended follow-up","route":"/key-papers/paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018/"},{"id":"paper-keynote-204-pembrolizumab-vs-brentuximab-rr-hodgkin-lancet-oncol-2021","kind":"paper","name":"KEYNOTE-204: pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma","route":"/key-papers/paper-keynote-204-pembrolizumab-vs-brentuximab-rr-hodgkin-lancet-oncol-2021/"}],"idea":[{"id":"idea-cd30-car-t-hodgkin","kind":"idea","name":"CD30 CAR-T for multiply relapsed Hodgkin lymphoma","route":"/ideas/idea-cd30-car-t-hodgkin/"}],"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}]}}